NOV03 for Dry Eye Disease Associated with Meibomian Gland Dysfunction: Results of the Randomized Phase 3 GOBI Study |
| |
| Affiliation: | 1. Tauber Eye Center, Kansas City, Missouri;2. Ophthalmology Associates, St. Louis, Missouri;3. Eye Research Foundation, Newport Beach, California;4. Novaliq GmbH, Heidelberg, Germany;5. Bausch + Lomb, Bridgewater, New Jersey |
| |
| Abstract: | |
| |
| Keywords: | Clinical trial Dry eye disease Meibomian gland dysfunction NOV03 Perfluorohexyloctane AE" },{" #name" :" keyword" ," $" :{" id" :" kwrd0040" }," $$" :[{" #name" :" text" ," _" :" adverse event BCVA" },{" #name" :" keyword" ," $" :{" id" :" kwrd0135" }," $$" :[{" #name" :" text" ," _" :" best-corrected visual acuity cCFS" },{" #name" :" keyword" ," $" :{" id" :" kwrd0050" }," $$" :[{" #name" :" text" ," _" :" central corneal fluorescein staining CI" },{" #name" :" keyword" ," $" :{" id" :" kwrd0060" }," $$" :[{" #name" :" text" ," _" :" confidence interval DED" },{" #name" :" keyword" ," $" :{" id" :" kwrd0070" }," $$" :[{" #name" :" text" ," _" :" dry eye disease FAS" },{" #name" :" keyword" ," $" :{" id" :" kwrd0080" }," $$" :[{" #name" :" text" ," _" :" full analysis set FDA" },{" #name" :" keyword" ," $" :{" id" :" kwrd0090" }," $$" :[{" #name" :" text" ," _" :" United States Food and Drug Administration LS" },{" #name" :" keyword" ," $" :{" id" :" kwrd0100" }," $$" :[{" #name" :" text" ," _" :" least square MGD" },{" #name" :" keyword" ," $" :{" id" :" kwrd0110" }," $$" :[{" #name" :" text" ," _" :" meibomian gland dysfunction tCFS" },{" #name" :" keyword" ," $" :{" id" :" kwrd0120" }," $$" :[{" #name" :" text" ," _" :" total corneal fluorescein staining VAS" },{" #name" :" keyword" ," $" :{" id" :" kwrd0130" }," $$" :[{" #name" :" text" ," _" :" visual analog scale |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
